SCHEMBL1337522

SCHEMBL1337522

COc1cccc(-c2ccc(NC(=O)c3ccccc3C(=O)O)cc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 4/20 0.65
PLG P00747 2/20 0.62
PLAT P00750 2/20 0.62
GAA P10253 2/20 0.62
KDM4E B2RXH2 1/20 0.62
TRPV1 Q8NER1 1/20 0.61
POLB P06746 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
MAPK1 P28482 1/20 0.59
GFER P55789 1/20 0.59
PTPN1 P18031 1/20 0.58
HCAR2 Q8TDS4 1/20 0.57
SMO Q99835 1/20 0.56
DHODH Q02127 2/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NR4A2 P43354 1/20 0.56
ALDH1A1 P00352 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337552 0.86 RXRA (0.61) GAAKDM4EPOLBMEN1KMT2A
SCHEMBL3209880 0.85 KDM4E (0.73) GAAKDM4ETRPV1POLBMEN1
SCHEMBL1335530 0.84 FABP1 (0.57) GAAKDM4EPOLBMEN1KMT2A
SCHEMBL1335706 0.84 IGF2BP2 (0.57) GAAPOLBMEN1KMT2AMAPK1
SCHEMBL1335695 0.83 NR1H4 (0.62) GAAPOLBMEN1KMT2AMAPK1
SCHEMBL1335741 0.83 GAA (0.61) GAAKDM4ETRPV1POLBMEN1
SCHEMBL12189549 0.83 NPC1 (0.72) GAAPOLBMEN1KMT2AMAPK1
SCHEMBL1336628 0.83 ALDH1A1 (0.79) KDM4EMEN1KMT2AGFERPTPN1
SCHEMBL29360103 0.83 ALDH1A1 (0.79) KDM4EMEN1KMT2AGFERPTPN1
SCHEMBL1337647 0.83 SMO (0.52) PLAUGAAKDM4EPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP claimed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US claimed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US claimed
EP-2566847-A1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS Icozen Therapeutics Pvt. Ltd. (IN) 2013-03-13 EP claimed
WO-2011138665-A1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-11-10 WO claimed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US claimed
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
EP-2566847-A1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS Icozen Therapeutics Pvt. Ltd. (IN) 2013-03-13 EP disclosed
WO-2011138665-A1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-11-10 WO disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR PLAU 3571/4885PLG 3564/4885PLAT 3487/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR PLAU 3571/4885PLG 3564/4885PLAT 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.